Radium-223 in Prostate Cancer REPLY

被引：33
|
作者：
Parker, Chris [1 ]
Sartor, Oliver [2 ]
机构：
[1] Royal Marsden Hosp, Sutton, Surrey, England
[2] Tulane Univ, Sch Med, New Orleans, LA 70112 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2013年 / 369卷 / 17期
关键词：
D O I：
10.1056/NEJMc1310231
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
To the Editor: In their editorial on the use of radium-223 for the treatment of bone metastases in prostate cancer, Vapiwala and Glatstein (July 18 issue)(1) provide an overview of the benefits of alpha-emitting radioisotopes. They focus on the results reported in the same issue of the Journal by Parker et al.,(2) who describe the association between the use of radium-223 dichloride and an observed increase in survival, as compared with placebo. In both the article and the editorial, the authors suggest that current radiopharmaceutical agents for bone pain palliation do not prolong survival, with the editorialists stating that the ...
引用
收藏
页码：1659 / 1660
页数：2
相关论文
共 50 条
  • [41] Optimal usage of radium-223 in metastatic castration-resistant prostate cancer
    Cha, Tai-Lung
    Wu, Tony Tong-Lin
    Vogelzang, Nicholas John
    Huang, Chao-Yuan
    Huang, Shu-Pin
    Lin, Chia-Chi
    Ou, Yen-Chuan
    Pang, See-Tong
    Shen, Daniel Heung-Yuan
    Wu, Wen-Jeng
    Chang, Wayne Yen-Hwa
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2017, 116 (11) : 825 - 836
  • [42] Radium-223 might benefit patients with hormone-refractory prostate cancer
    不详
    NATURE CLINICAL PRACTICE UROLOGY, 2007, 4 (10): : 523 - 524
  • [43] Radium-223 might benefit patients with hormone-refractory prostate cancer
    Nature Clinical Practice Urology, 2007, 4 : 523 - 524
  • [44] The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer
    Heinrich, Daniel
    Bektic, Jasmin
    Bergman, Andries M.
    Caffo, Orazio
    Cathomas, Richard
    Chi, Kim N.
    Daugaard, Gedske
    Keizman, Daniel
    Kindblom, Jon
    Kramer, Gero
    Olmos, David
    Omlin, Aurelius
    Sridhar, Srikala S.
    Tucci, Marcello
    van Oort, Inge
    Nilsson, Sten
    CLINICAL GENITOURINARY CANCER, 2018, 16 (01) : E223 - E231
  • [45] Survival and immune analysis of radium-223 in patients with metastatic prostate cancer.
    Kim, Joseph W.
    Shin, Min
    Kang, Youna
    Kang, Insoo
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] Biokinetics and dosimetry of radium-223 in the cancer patient
    Fisher, D. R.
    Ramdahl, T.
    Bruland, O. S.
    Larsen, R. H.
    Harmenberg, J.
    Nilsson, S.
    Dornish, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S199 - S199
  • [47] Radium-223 in Metastatic Castration Resistant Prostate Cancer (mCRPC): a Single Cancer Centre Experience
    Tsoukalas, N.
    Morgui, M. Saigi
    Mills, C.
    Lewington, V.
    Chowdhury, S.
    Rudman, S.
    CLINICAL ONCOLOGY, 2016, 28 (05) : E15 - E15
  • [48] Metastatic castration resistant prostate cancer patients' experience with Radium-223 treatment in Japan
    Akakura, Koichiro
    Uemura, Hiroji
    Kawakami, Satoru
    Yokomizo, Akira
    Nakamura, Motonobu
    Nishimura, Kazuo
    Komori, Tetsushi
    Ledesma, Dianne Athene
    FUTURE ONCOLOGY, 2024, 20 (12) : 781 - 798
  • [49] Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
    Yong Du
    Ignasi Carrio
    Giuseppe De Vincentis
    Stefano Fanti
    Harun Ilhan
    Caroline Mommsen
    Egbert Nitzsche
    Francis Sundram
    Wouter Vogel
    Wim Oyen
    Val Lewington
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1671 - 1678
  • [50] Radium-223 and metastatic castration-resistant prostate cancer: All that glitters is not gold
    Aprile, Carlo
    Persico, Marco G.
    Lodola, Lorenzo
    Buroni, Federica E.
    WORLD JOURNAL OF RADIOLOGY, 2016, 8 (10): : 816 - 818
12345